View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 14, 2022

BenevolentAI and AstraZeneca expand drug discovery partnership

The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.

BenevolentAI and AstraZeneca have announced the expansion of their artificial intelligence (AI)-powered drug discovery partnership to include disease areas, systemic lupus erythematosus (SLE) and heart failure (HF).

The three-year collaboration extension comprises an upfront payment, funding for research, payments on meeting development milestones and tiered royalty payments on revenues in the future.

The latest expansion builds on the long-term partnership entered in 2019.

During that year, the companies collaborated to leverage AI and machine learning to discover and develop new therapies for the treatment of chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

BenevolentAI noted that the alliance accomplished two key milestones, with the addition of the first new targets to AstraZeneca’s portfolio for CKD as well as IPF.

A disease agnostic, the Benevolent Platform can be applied to any ailment to generate new targets on a large scale. 

Leveraging the Benevolent Platform and biomedical Knowledge Graph will offer the scientists and technologists of BenevolentAI and AstraZeneca an improved understanding of the underlying disease mechanisms and identify new targets. 

Knowledge Graph comprises AstraZeneca data with public and licensed data from scientific literature, genetics, patents, clinical trials and chemistry among others.

AstraZeneca BioPharmaceuticals Research and Development (R&D) executive vice-president Mene Pangalos said: “Systemic lupus erythematosus and heart failure are debilitating diseases with high unmet patient needs. 

“Our work to date with BenevolentAI has been truly collaborative and we look forward to continuing to work side-by-side with them to better understand the underlying mechanisms of these complex diseases and more quickly identify new potential drug targets.”

A complex autoimmune ailment, SLE can impact several organ systems and patients frequently report insufficient disease control, extended organ damage and poor health-associated quality of life. 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology